Equities Analysts Set Expectations for STERIS Q2 Earnings

STERIS plc (NYSE:STE) – Equities research analysts at Zacks Research decreased their Q2 2026 earnings per share estimates for shares of STERIS in a note issued to investors on Tuesday, September 16th. Zacks Research analyst Team now expects that the medical equipment provider will post earnings of $2.37 per share for the quarter, down from their previous estimate of $2.82. The consensus estimate for STERIS’s current full-year earnings is $9.08 per share. Zacks Research also issued estimates for STERIS’s Q3 2026 earnings at $2.57 EPS, Q4 2026 earnings at $2.85 EPS, FY2026 earnings at $10.13 EPS, Q1 2027 earnings at $2.46 EPS, Q2 2027 earnings at $2.86 EPS, Q3 2027 earnings at $2.79 EPS, Q4 2027 earnings at $2.64 EPS, FY2027 earnings at $10.75 EPS, Q1 2028 earnings at $3.01 EPS and FY2028 earnings at $12.21 EPS.

STERIS (NYSE:STE) last posted its earnings results on Wednesday, August 6th. The medical equipment provider reported $2.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.32 by $0.02. STERIS had a return on equity of 14.17% and a net margin of 11.61%.The company had revenue of $1.40 billion for the quarter, compared to analyst estimates of $1.36 billion. During the same quarter in the previous year, the firm earned $2.03 earnings per share. The firm’s quarterly revenue was up 8.8% compared to the same quarter last year.

A number of other equities research analysts have also recently commented on the company. Jefferies Financial Group initiated coverage on STERIS in a research note on Thursday, May 29th. They issued a “hold” rating and a $263.00 price target for the company. Morgan Stanley increased their price objective on shares of STERIS from $276.00 to $295.00 and gave the company an “overweight” rating in a research report on Friday, August 8th. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Finally, KeyCorp lifted their price target on STERIS from $277.00 to $288.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 22nd. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $273.50.

STERIS Price Performance

NYSE STE opened at $248.68 on Thursday. STERIS has a 12-month low of $200.98 and a 12-month high of $253.00. The firm’s fifty day simple moving average is $238.35 and its two-hundred day simple moving average is $233.66. The company has a current ratio of 2.22, a quick ratio of 1.53 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $24.49 billion, a P/E ratio of 38.08 and a beta of 0.95.

STERIS Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 26th. Stockholders of record on Thursday, September 4th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.0%. This is a boost from STERIS’s previous quarterly dividend of $0.57. The ex-dividend date is Thursday, September 4th. STERIS’s dividend payout ratio (DPR) is currently 38.59%.

Insider Buying and Selling

In other STERIS news, CAO Karen L. Burton sold 7,900 shares of the firm’s stock in a transaction on Monday, August 11th. The stock was sold at an average price of $241.73, for a total value of $1,909,667.00. Following the completion of the sale, the chief accounting officer directly owned 5,994 shares of the company’s stock, valued at $1,448,929.62. This trade represents a 56.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Cynthia L. Feldmann sold 3,495 shares of STERIS stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $241.56, for a total transaction of $844,252.20. Following the transaction, the director directly owned 705 shares in the company, valued at $170,299.80. This trade represents a 83.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,709 shares of company stock valued at $4,546,940 in the last quarter. Corporate insiders own 1.07% of the company’s stock.

Institutional Investors Weigh In On STERIS

Institutional investors have recently made changes to their positions in the stock. Osaic Holdings Inc. raised its position in STERIS by 2.8% in the second quarter. Osaic Holdings Inc. now owns 10,376 shares of the medical equipment provider’s stock valued at $2,484,000 after purchasing an additional 287 shares during the period. American Trust purchased a new stake in shares of STERIS in the 2nd quarter valued at $222,000. Orion Porfolio Solutions LLC lifted its stake in STERIS by 5.5% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 15,204 shares of the medical equipment provider’s stock worth $3,652,000 after acquiring an additional 788 shares in the last quarter. Thrivent Financial for Lutherans boosted its holdings in STERIS by 49.2% during the 2nd quarter. Thrivent Financial for Lutherans now owns 159,864 shares of the medical equipment provider’s stock valued at $38,402,000 after acquiring an additional 52,746 shares during the period. Finally, Neuberger Berman Group LLC lifted its position in shares of STERIS by 64.7% during the second quarter. Neuberger Berman Group LLC now owns 19,416 shares of the medical equipment provider’s stock worth $4,664,000 after purchasing an additional 7,630 shares in the last quarter. 94.69% of the stock is currently owned by institutional investors and hedge funds.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.